Klaria Year-End Report 1 January-
Summary of the Year-End Report
Successful rights issue brought 59.2 MSEK to Klaria
New collaboration agreement signed with
- Net sales amounted to 2.2 MSEK (0.0 MSEK)
- Other income amounted to 0.2 MSEK (6.2 MSEK)
- R&D costs for the period amounted to 8.6 MSEK (28.1 MSEK)
- Profit after tax amounted to -12.9 MSEK (-24.8 MSEK)
- Earnings per share for the quarter amounted to
- Cash flow from operating activities amounted to -10.7 MSEK (-14.6 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 16.8 MSEK (25.5 MSEK)
- Equity as of
- Net sales amounted to 5.9 MSEK (0.0 MSEK)
- Other income amounted to 0,7 MSEK (37.5 MSEK)
- R&D costs for the period amounted to 51.4 MSEK (63.5 MSEK)
- Profit after tax amounted to -63.8 MSEK (-53.5 MSEK)
- Earnings per share for the quarter amounted to
- Cash flow from operating activities amounted to -49.8 MSEK (-24.8 MSEK)
- Cash and cash equivalents in the parent company amounted to 15.5 MSEK (9.1 MSEK)
- Equity in the parent company amounted to 175.3 MSEK (158.4 MSEK)
For more information, visit the
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99
This is
Klaria (
https://news.cision.com/klaria-pharma-holding-ab/r/klaria-year-end-report,c3712466
https://mb.cision.com/Main/12655/3712466/1840037.pdf
(c) 2023 Cision. All rights reserved., source